Cerebrolysin

Cerebrolysin is a research compound consisting of a standardized mixture of small peptide fragments and free amino acids derived from porcine brain protein, rather than a single defined molecule. It is grouped among cognitive and neuroprotective research compounds studied in laboratory settings.

Cerebrolysin is a research compound: a mixture of small peptide fragments and free amino acids produced from porcine (pig) brain tissue.

• Composition: peptide fragments and amino acids, not a single defined molecule.
• Research category: grouped with cognitive and neuroprotective research compounds studied in laboratory settings.
• Regulatory status: not FDA-approved in the United States; not authorized for human or animal use.

Cerebrolysin is a peptide-based preparation derived from porcine brain protein, typically supplied as a lyophilized powder for laboratory research use only. Because it ships freeze-dried, it must be reconstituted before any bench work can proceed, which is why listings are paired with dedicated reconstitution kits rather than pre-mixed solutions.

Our reconstitution kits are built around standard hardware. Our pens take standard 3 ml (300-unit) glass cartridges with the 11 mm long plunger (stopper), the cartridge we sell. 3 ml cartridges are also made with a shorter, about 8 mm plunger, and a pen is built for one height, so check that a cartridge from another source has the 11 mm long plunger before loading it; the glass looks identical from the outside. We have not tested our hardware against third-party pen or cartridge manufacturers, so compatibility outside our own line cannot be confirmed.

What it is

Cerebrolysin is not one molecule — it is a standardized mixture (produced to the same recipe each batch) of neuropeptides and free amino acids derived from purified pig brain protein. Enzymes act like molecular scissors, cutting the source protein into very small fragments, nearly all under 10 kilodaltons (a unit describing molecular size).

• Neuropeptides — short protein chains that act as signaling molecules in nervous tissue.
• Amino acids — the individual building blocks that link together to form proteins.
• Kilodalton (kDa) — a unit of molecular weight; smaller fragments pass more easily through experimental membranes and assays.

Because of this composition, Cerebrolysin is generally classified in the literature as a neurotrophic or neuropeptide preparation — a category of study describing composition and research interest, not a confirmed outcome. This overview covers composition only and makes no claims about safety, efficacy, or suitability for use in humans or animals.

Research context and categorization

Investigational Scope

Cerebrolysin is categorized in the research literature under cognitive and neuroprotective research. "Neuroprotective" describes research concerned with protecting nerve and brain cells. Published studies discuss it in relation to three broad areas: neuronal survival (mechanisms tied to keeping brain cells alive in cell and animal models), neuroplasticity (the nervous system's capacity to reorganize connections, comparable to a road network rerouting around a closed road), and central nervous system recovery processes (the brain and spinal cord).

The literature includes research contexts such as stroke recovery, traumatic brain injury, and various forms of dementia, including Alzheimer-related cognitive decline, plus general cognitive-function research. These categories describe how the compound is discussed and classified academically, not an approved or intended use.

Clinical Evidence and Efficacy

From a U.S. regulatory standpoint, all of the above remains investigational: still being studied, unconfirmed, and not proven. The published evidence is mixed rather than conclusive. Some dementia-focused trials have reported findings researchers describe as suggestive of benefit.

By contrast, a major stroke trial did not meet its primary endpoint, the main outcome measure it was designed to test. Systematic reviews, which pool and statistically analyze results across multiple trials, have rated much of this combined evidence as low quality and have flagged specific results as warranting closer scrutiny before being treated as reliable.

Cerebrolysin therefore remains an actively studied and debated research subject. Findings reported in the literature are unconfirmed and unapproved for medical use in the United States, and nothing here should be read as evidence of safety or effectiveness.

Key point: Cerebrolysin is an investigational research agent with a mixed evidence base and no approved medical use in the United States.

Status

• Regulatory status: Cerebrolysin is available for research use only in the United States and is not FDA-approved for any indication. It holds marketing approval in roughly 50 other countries, mainly across Europe and Asia, where it is registered for conditions such as stroke, traumatic brain injury, and dementia. Approval in those markets has no bearing on its regulatory status in the U.S., where it remains a research compound only.
• Sport status: Cerebrolysin is not named on the current WADA Prohibited List (the World Anti-Doping Agency's annual list of substances banned in sport) and is not classified as a listed peptide hormone or growth factor. The list is revised yearly and includes broad catch-all language for related substances, so status should always be verified against the latest published list before any competition context.

Reconstitution notes (general)

For a standard lyophilized (freeze-dried) research peptide, concentration equals the milligrams of compound in the vial divided by the millilitres of diluent added. For example, 60 mg mixed with 2 mL of bacteriostatic water gives a concentration of 30 mg per mL.

A reconstitution calculator is available at peptide calculator. Note that this general powder formula does not describe how Cerebrolysin is typically supplied (see below).

Diluent choice matters for solution stability. Bacteriostatic water contains 0.9% benzyl alcohol as a preservative; published peptide-stability literature notes that preservative concentration, pH, and storage temperature all influence how quickly a reconstituted solution degrades, so diluent selection and cold storage should follow the specific compound's documented handling profile rather than a single general rule.

Dilution and handling notes (compound-specific)

Supply and Workflow Exception

Cerebrolysin is an exception to the usual reconstitution workflow described elsewhere on this site. Reference literature describes it as supplied ready-to-use inside sealed glass ampoules — commonly 2 mL, 5 mL, or 10 mL amber glass — rather than as a freeze-dried powder that requires mixing with bacteriostatic water.

Because the ampoule already holds solution, there is normally no reconstitution step: no powder to dissolve, and none of the gelling, cloudiness, or particle-formation issues that some concentrated peptide powders can show on reconstitution.

Dilution and Storage Constraints

Where reference material discusses dilution, it applies only to larger volumes prepared for slow infusion in a laboratory setting. In that context, the ampoule solution is combined immediately before use with a compatible carrier, such as:

• 0.9% sodium chloride — a simple saltwater solution
• 5% glucose solution — a simple sugar-water solution
• Ringer's lactate — a balanced salt solution

Handling points worth noting for reference purposes:

• An opened ampoule is no longer sealed or sterile once broken. Reference literature classifies any diluted preparation as single-use, with no extended storage after opening — the ampoule's contents are meant for prompt use once broken open, not for later sessions.
• Cerebrolysin is described in reference sources as a clear, amber-tinted liquid, visibly different in appearance from a colorless reconstituted peptide solution. This means the visual baseline for "does this look right" differs from the powder-based compounds discussed elsewhere on this site, since color and clarity expectations are not the same across preparation types.

Handling and storage

Temperature and Storage Guidelines

General cold-chain handling for this class of material means keeping it refrigerated at roughly 2 to 8 degrees Celsius, stored away from direct light, and protected from freezing.

Pen and Cartridge Compatibility

Our pens take standard 3 ml (300-unit) glass cartridges with the 11 mm long plunger (stopper), the cartridge we sell. 3 ml cartridges are also made with a shorter, about 8 mm plunger, and a pen is built for one height, so check that a cartridge from another source has the 11 mm long plunger before loading it; the glass looks identical from the outside. We have not tested our hardware against other manufacturers' pens or cartridges, so fit with third-party equipment cannot be confirmed either way.

Access and Quality Control

When accessing any vial or ampoule through a rubber stopper, wipe the stopper with an alcohol swab before access and label the container with the date it was opened or mixed.

Reconstituted or opened peptide solutions are commonly assigned a refrigerated working window of about four weeks. However, ready-to-use ampoule solutions like Cerebrolysin are typically single-use once opened.

Discard any solution that becomes cloudy, changes color beyond its normal appearance, or shows particles or floating material.

Frequently asked questions

More in our peptide pens collection.